Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124829842 | 12482984 | 2 | F | 20160129 | 20160203 | 20160620 | 20160824 | EXP | MX-ELI_LILLY_AND_COMPANY-MX201602002770 | ELI LILLY AND CO | 41.46 | YR | F | Y | 0.00000 | 20160824 | CN | MX | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124829842 | 12482984 | 1 | PS | INSULIN, LISPRO | INSULIN LISPRO | 1 | Unknown | 18 U, EACH MORNING | 20563 | 18 | IU | QD | |||||||
| 124829842 | 12482984 | 2 | SS | INSULIN, LISPRO | INSULIN LISPRO | 1 | Unknown | 8 U, EACH EVENING | 20563 | 8 | IU | QD | |||||||
| 124829842 | 12482984 | 3 | SS | INSULIN, LISPRO | INSULIN LISPRO | 1 | Unknown | 20 IU, EACH MORNING | 20563 | 20 | IU | QD | |||||||
| 124829842 | 12482984 | 4 | SS | INSULIN, LISPRO | INSULIN LISPRO | 1 | Unknown | 68 IU, QD | 20563 | 68 | IU | QD | |||||||
| 124829842 | 12482984 | 5 | SS | INSULIN, LISPRO | INSULIN LISPRO | 1 | Unknown | 15 IU, EACH EVENING | 20563 | 15 | IU | QD | |||||||
| 124829842 | 12482984 | 6 | C | FOLIC ACID. | FOLIC ACID | 1 | Oral | UNK | 0 | ||||||||||
| 124829842 | 12482984 | 7 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | UNK, UNKNOWN | 0 | ||||||||||
| 124829842 | 12482984 | 8 | C | CALCIUM | CALCIUM | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 124829842 | 12482984 | 9 | C | CALCIUM | CALCIUM | 1 | U | 0 | |||||||||||
| 124829842 | 12482984 | 10 | C | TAPAZOL /00022901/ | 2 | Oral | 5 MG, TID | 0 | 5 | MG | TID | ||||||||
| 124829842 | 12482984 | 11 | C | TAPAZOL /00022901/ | 2 | 0 | |||||||||||||
| 124829842 | 12482984 | 12 | C | PROPANOL | PROPRANOLOL HYDROCHLORIDE | 1 | Oral | UNK, QD | 0 | QD | |||||||||
| 124829842 | 12482984 | 13 | C | PROPANOL | PROPRANOLOL HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124829842 | 12482984 | 1 | Gestational diabetes |
| 124829842 | 12482984 | 6 | Vitamin supplementation |
| 124829842 | 12482984 | 7 | Vitamin supplementation |
| 124829842 | 12482984 | 8 | Hyperthyroidism |
| 124829842 | 12482984 | 9 | Vitamin supplementation |
| 124829842 | 12482984 | 10 | Thyroid disorder |
| 124829842 | 12482984 | 11 | Hyperthyroidism |
| 124829842 | 12482984 | 12 | Thyroid disorder |
| 124829842 | 12482984 | 13 | Hyperthyroidism |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124829842 | 12482984 | HO |
| 124829842 | 12482984 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124829842 | 12482984 | Cephalo-pelvic disproportion | |
| 124829842 | 12482984 | Exposure during breast feeding | |
| 124829842 | 12482984 | Gestational diabetes | |
| 124829842 | 12482984 | Maternal exposure during pregnancy | |
| 124829842 | 12482984 | Thyroid disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124829842 | 12482984 | 1 | 20160129 | 0 | ||
| 124829842 | 12482984 | 2 | 20160129 | 0 | ||
| 124829842 | 12482984 | 10 | 201601 | 0 | ||
| 124829842 | 12482984 | 12 | 201601 | 0 |